Dr. Stuart W. Zarich, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 171
Licensed in Connecticut since 1996, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: State University of Ny Upstate Medical University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
CT license 035245 (first issued 1996; active) -
Internal Medicine Physician
CT license 035245 (first issued 1996; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bridgeport Hospital Bridgeport, CT
Medical groups
- Yale University (2,645 clinicians)
- Northeast Medical Group Inc (1,360 clinicians)
- Bridgeport Hospital (136 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 171
- Services billed
- 305
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 77 | 77 |
| Ultrasound of heart, follow-up | 34 | 32 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | 25 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 25 | 24 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 23 | 22 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 19 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Bridgeport, CT | 136 |
| Atorvastatin Calcium Other prescribers in Bridgeport, CT | 75 |
| Metoprolol Succinate Other prescribers in Bridgeport, CT | 61 |
| Amlodipine Besylate Other prescribers in Bridgeport, CT | 55 |
| Eliquis (apixaban) Other prescribers in Bridgeport, CT | 54 |
| Valsartan-Hydrochlorothiazide (valsartan/hydrochlorothiazide) Other prescribers in Bridgeport, CT | 45 |
| Furosemide Other prescribers in Bridgeport, CT | 45 |
| Carvedilol Other prescribers in Bridgeport, CT | 43 |
| Jardiance (empagliflozin) Other prescribers in Bridgeport, CT | 37 |
| Olmesartan Medoxomil Other prescribers in Bridgeport, CT | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $275 in total to this clinician.
| Alnylam Pharmaceuticals Inc. | $150 |
|---|---|
| Novo Nordisk Inc | $125 |
| Food and Beverage | $275 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $597,673 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly and Company · Active, not recruiting · NCT06662383 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim Pharma GmbH & Co.kg - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.